Generic-drug firms, medical-device makers and health insurers are working to introduce minor changes to the health reform bill as top Democrats in both chambers of Congress work on the final version, according to this Reuters analysis. Generics companies want the measure to provide more incentives for the adoption of generic treatments, while device firms want the bill to delay until at least 2013 a proposed $20 billion tax during the next decade. Meanwhile, pharmaceutical and biotech firms do not plan to vie for last-minute changes to the measure.

Full Story:

Related Summaries